Ultralife Corporation (NASDAQ: ULBI) reported operating
income of $1.5 million on revenue of $25.8 million for the first
quarter ended March 31, 2020 compared to operating income of $0.5
million on revenue of $18.9 million for the first quarter of
2019.
“Ultralife posted strong results for the first quarter,
delivering a leveraged operating profit of $1.5 million, up 171%
over last year, on a 37% increase in revenue while contending with
COVID-19 impacts including a month-long shutdown in China and
supply chain disruptions,” said Michael D. Popielec, President and
Chief Executive Officer. “As an essential supplier, while ensuring
the health and safety of our employees by implementing the
protocols established by state and federal public health officials,
we are striving to ensure an uninterrupted flow of our mission
critical products serving medical device, first responder, public
safety, energy and national security customers. We are also
investing approximately $1 million in the second quarter for
additional test equipment to meet the increased demand for our
power supplies for ventilators, respirators and infusion
pumps.”
Concluded Mr. Popielec, “With a backlog increasing approximately
20% over year-end 2019, ample liquidity, end-market diversity and
tight control over discretionary spending, we are well positioned
to both sustain operations and continue investing in growth
initiatives.”
First Quarter 2020 Financial Results
Revenue was $25.8 million, an increase of $6.9 million, or
36.7%, compared to $18.9 million for the first quarter of 2019
reflecting the addition of Southwest Electronic Energy Corporation
(“SWE”) and higher Communications Systems sales. Overall,
commercial sales increased 47.9% while government/defense sales
increased 24.1% from the 2019 period. Battery & Energy
Products revenues were $20.8 million, compared to $16.0 million
last year, primarily reflecting the SWE acquisition.
Communications Systems sales grew 75.2% to $5.1 million compared to
$2.9 million for the same period last year primarily reflecting
shipments of vehicle amplifier-adaptor systems to support the U.S.
Army’s Network Modernization initiatives under the delivery orders
announced in October 2018.
Gross profit was $7.3 million, or 28.4% of revenue, compared to
$5.1 million, or 26.9% of revenue, for the same quarter a year
ago. Battery & Energy Products’ gross margin was 25.6%,
compared to 27.6% last year, reflecting a February government
mandated shutdown of our China operation in response to the
COVID-19. Communications Systems gross margin was
39.9%, compared to 23.4% last year, due to the transition of
vehicle amplifier-adaptor systems for the U.S. Army to higher
volume production as well as sales mix.
Operating expenses were $5.9 million compared to
$4.5 million last year reflecting the addition of SWE and an 11.8%
increase in engineering and technology expenses for new product
development and testing. Operating expenses were 22.7% of
revenue compared to 24.0% of revenue for the year-earlier period,
an improvement of 130 basis points.
Operating income was $1.5 million compared to $0.5 million last
year, and operating margin was 5.7% compared to 2.9% last
year.
Net income was $1.1 million or $0.07 per diluted share using the
U.S. statutory tax rate, compared to net income of $.4 million, or
$0.03 per diluted share, for the first quarter of 2019, a 151.3%
increase. Adjusted EPS was $0.08 on a diluted basis for the
first quarter of 2020, representing a 212.4% increase over the 2019
period. Adjusted EPS excludes the provision for deferred
income taxes which primarily represents non-cash charges of
approximately $0.2 million for U.S. taxes which will be fully
offset by net operating loss carryforwards and other tax credits
for the foreseeable future.
Adjusted EBITDA, defined as EBITDA including non-cash,
stock-based compensation expense, was $2.5 million for the first
quarter of 2020, an increase of 109.5% over the year-earlier
period. Adjusted EBITDA margin was 9.8% compared to 6.4% for
the first quarter of 2019. For the trailing twelve-month
period, Adjusted EBITDA was $12.3 million or 10.8% of revenues.
See the “Non-GAAP Financial Measures” section of this release
for a reconciliation of Adjusted EPS to EPS and Adjusted EBITDA to
Net Income Attributable to Ultralife Corporation.
About Ultralife Corporation
Ultralife Corporation serves its markets with products and
services ranging from power solutions to communications and
electronics systems. Through its engineering and collaborative
approach to problem solving, Ultralife serves government, defense
and commercial customers across the globe.
Headquartered in Newark, New York, the Company's business
segments include Battery & Energy Products and Communications
Systems. Ultralife has operations in North America, Europe and
Asia. For more information, visit www.ultralifecorporation.com.
Conference Call Information
Ultralife will hold its first quarter earnings conference call
today at 8:30 AM ET. To participate in the live call, please dial
(800) 915-4836 at least ten minutes before the scheduled start
time, identify yourself and ask for the Ultralife call. A live
webcast of the conference call will be available to investors in
the Events & Presentations section of the Company's website at
http://investor.ultralifecorporation.com. For those who cannot
listen to the live broadcast, a replay of the webcast will be
available shortly after the call at the same location.
This press release may contain forward-looking statements based
on current expectations that involve a number of risks and
uncertainties. The potential risks and uncertainties that could
cause actual results to differ materially include potential
reductions in revenues from key customers, acceptance of our new
products on a global basis and uncertain global economic
conditions. The Company cautions investors not to place undue
reliance on forward-looking statements, which reflect the Company's
analysis only as of today's date. The Company undertakes no
obligation to publicly update forward-looking statements to reflect
subsequent events or circumstances. Further information on
these factors and other factors that could affect Ultralife’s
financial results is included in Ultralife’s Securities and
Exchange Commission (SEC) filings, including the latest Annual
Report on Form 10-K.
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED BALANCE SHEETS(Dollars in
Thousands) |
(Unaudited) |
|
ASSETS |
|
|
March 31,2020 |
|
December 31,2019 |
Current
Assets: |
|
|
|
Cash |
$6,109 |
|
$7,405 |
Trade Accounts Receivable, Net |
35,750 |
|
30,106 |
Inventories, Net |
28,979 |
|
29,759 |
Prepaid Expenses and Other Current Assets |
2,730 |
|
3,103 |
Total Current Assets |
73,568 |
|
70,373 |
|
|
|
|
Property,
Equipment and Improvements, Net |
22,039 |
|
22,525 |
Goodwill |
26,468 |
|
26,753 |
Other Intangible
Assets, Net |
9,405 |
|
9,721 |
Deferred Income
Taxes, Net |
12,887 |
|
13,222 |
Other Non-Current
Assets |
1,783 |
|
1,963 |
Total Assets |
$146,150 |
|
$144,557 |
|
LIABILITIES AND SHAREHOLDERS'
EQUITY |
|
Current
Liabilities: |
|
|
|
Accounts Payable |
$11,731 |
|
$9,388 |
Current Portion of Long-Term Debt |
1,467 |
|
1,372 |
Accrued Compensation and Related Benefits |
1,597 |
|
1,655 |
Accrued Expenses and Other Current Liabilities |
4,133 |
|
4,775 |
Total Current Liabilities |
18,928 |
|
17,190 |
Long-Term
Debt |
15,354 |
|
15,780 |
Deferred Income
Taxes |
496 |
|
559 |
Other Non-Current
Liabilities |
1,103 |
|
1,278 |
Total Liabilities |
35,881 |
|
34,807 |
|
|
|
|
Shareholders'
Equity: |
|
|
|
Common Stock |
2,028 |
|
2,026 |
Capital in Excess of Par Value |
184,550 |
|
184,292 |
Accumulated Deficit |
(51,771) |
|
(52,830) |
Accumulated Other Comprehensive Loss |
(3,338) |
|
(2,531) |
Treasury Stock |
(21,239) |
|
(21,231) |
Total Ultralife Equity |
110,230 |
|
109,726 |
Non-Controlling
Interest |
39 |
|
24 |
Total Shareholders’ Equity |
110,269 |
|
109,750 |
|
|
|
|
Total Liabilities and Shareholders' Equity |
$146,150 |
|
$144,557 |
|
|
|
|
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF INCOME (In
Thousands Except Per Share Amounts) |
(Unaudited) |
|
|
|
Three-Month Period Ended |
|
March 31, |
|
March 31, |
|
2020 |
|
2019 |
Revenues: |
|
|
|
Battery & Energy Products |
$20,761 |
|
$15,998 |
Communications Systems |
5,053 |
|
2,884 |
Total
Revenues |
25,814 |
|
18,882 |
|
|
|
|
Cost of Products
Sold: |
|
|
|
Battery & Energy Products |
15,445 |
|
11,588 |
Communications Systems |
3,035 |
|
2,210 |
Total Cost of Products
Sold |
18,480 |
|
13,798 |
|
|
|
|
Gross Profit |
7,334 |
|
5,084 |
|
|
|
|
Operating
Expenses: |
|
|
|
Research and Development |
1,548 |
|
1,036 |
Selling, General and Administrative |
4,301 |
|
3,500 |
Total Operating
Expenses |
5,849 |
|
4,536 |
|
|
|
|
Operating
Income |
1,485 |
|
548 |
|
|
|
|
Other
Expense |
(92) |
|
(58) |
Income Before Income
Tax Provision |
1,393 |
|
490 |
|
|
|
|
Income Tax Provision |
(319) |
|
(41) |
|
|
|
|
Net
Income |
1,074 |
|
449 |
|
|
|
|
Net Income Attributable to
Non-Controlling Interest |
(15) |
|
(24) |
|
|
|
|
Net Income
Attributable to Ultralife Corporation |
$1,059 |
|
$425 |
|
|
|
|
Net Income Per Share
Attributable to Ultralife Common Shareholders – Basic |
$0.07 |
|
$0.03 |
|
|
|
|
Net Income Per Share
Attributable to Ultralife Common Shareholders –
Diluted |
$0.07 |
|
$0.03 |
|
|
|
|
Weighted Average Shares
Outstanding – Basic |
15,875 |
|
15,740 |
|
|
|
|
Weighted Average Shares
Outstanding – Diluted |
16,087 |
|
16,225 |
|
|
|
|
Non-GAAP Financial Measures:
Adjusted Earnings Per Share
In evaluating our business, we consider and use Adjusted EPS, a
non-GAAP financial measure, as a supplemental measure of our
business performance in addition to U.S. GAAP financial
measures. We define Adjusted EPS as net income
attributable to Ultralife Corporation excluding the provision for
deferred taxes divided by our weighted average shares outstanding
on both a basic and diluted basis. We believe that this
information is useful in providing period-to-period comparisons of
our results by reflecting the portion of our tax provision that
will be offset by our U.S. net operating loss carryforwards and
other tax credits for the foreseeable future. We reconcile
Adjusted EPS to EPS, the most comparable financial measure under
U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).
Neither current nor potential investors in our securities should
rely on Adjusted EPS as a substitute for any GAAP measures and we
encourage investors to review the following reconciliation of
Adjusted EPS to EPS and net income attributable to Ultralife
Corporation.
|
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CALCULATION OF ADJUSTED EPS |
(In Thousands Except Per Share Amounts) |
(Unaudited) |
|
|
Three-Month Period Ended |
|
March 31, 2020 |
|
March 31, 2019 |
|
Amount |
|
PerBasicShare |
|
PerDilutedShare |
|
Amount |
|
PerBasicShare |
|
PerDilutedShare |
Net Income Attributable to
Ultralife Corporation |
$1,059 |
|
$.07 |
|
$.07 |
|
$425 |
|
$0.03 |
|
$0.03 |
Deferred Tax Provision |
242 |
|
.01 |
|
.01 |
|
(5) |
|
- |
|
- |
Adjusted Net Income |
$1,301 |
|
$.08 |
|
$.08 |
|
$420 |
|
$.03 |
|
$.03 |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares
Outstanding |
|
|
15,875 |
|
16,087 |
|
|
|
15,740 |
|
16,225 |
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
In evaluating our business, we consider and use Adjusted EBITDA,
a non-GAAP financial measure, as a supplemental measure of our
operating performance in addition to U.S. GAAP financial measures.
We define Adjusted EBITDA as net income attributable to Ultralife
Corporation before net interest expense, provision (benefit) for
income taxes, depreciation and amortization, and stock-based
compensation expense, plus/minus expense/income that we do not
consider reflective of our ongoing continuing operations. We
reconcile Adjusted EBITDA to net income attributable to Ultralife
Corporation, the most comparable financial measure under
U.S. GAAP. Neither current nor potential investors in
our securities should rely on Adjusted EBITDA as a substitute for
any GAAP measures and we encourage investors to review the
following reconciliation of Adjusted EBITDA to net income
attributable to Ultralife Corporation.
|
ULTRALIFE CORPORATION AND SUBSIDIARIES |
CALCULATION OF ADJUSTED EBITDA |
(Dollars in Thousands) |
(Unaudited) |
|
|
Three-Month Period Ended |
|
March 31, 2020 |
|
March 31, 2019 |
|
|
|
|
Net Income Attributable to
Ultralife Corporation |
$1,059 |
|
$425 |
Adjustments: |
|
|
|
Interest and Financing Expense, Net |
174 |
|
5 |
Income Tax Provision |
319 |
|
41 |
Depreciation Expense |
579 |
|
447 |
Amortization of Intangible Assets and Financing Fees |
161 |
|
101 |
Stock-Based Compensation Expense |
230 |
|
185 |
Adjusted EBITDA |
$2,522 |
|
$1,204 |
|
|
|
|
Company Contact: |
Investor Relations Contact: |
Ultralife Corporation |
LHA |
Philip A. Fain |
Jody Burfening |
(315) 210-6110 |
(212) 838-3777 |
pfain@ulbi.com |
jburfening@lhai.com |
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ultralife (NASDAQ:ULBI)
Historical Stock Chart
From Apr 2023 to Apr 2024